Pfizer 1Q Revenues: $13.0 billion (+20%) 1Q Earnings: $3.0 billion (+27%) Comments: Innovative Product sales were $7.0 billion, up 23% driven by Eliquis globally, Lyrica and Xeljanz both primarily in the U.S., Enbrel in most international markets and Chantix primarily in the U.S. Global Vaccines sales were $1.6 billion, up 18%. Global Oncology revenues were $1.0 billion, up 90% driven by Ibrance for advanced breast cancer and, to a lesser extent, stronger demand for Sutent and Xalkori i...